<DOC>
	<DOC>NCT02333370</DOC>
	<brief_summary>The purpose of the Phase Ib is to: 1. determine the recommended dose of LEE011 in combination with a standard dose of letrozole as well as to provide additional safety and anti-tumor activity data in Asian non-Japanese patients 2. determine the recommended dose of LEE011 in combination with a standard dose of letrozole as well as to provide additional safety and activity data in Japanese patients 3. evaluate the safety and anti-tumor activity of LEE011 at the RP2D established in the dose escalation part in combination with a standard dose of letrozole, fulvestrant or tamoxifen plus goserelin in Japanese patients.</brief_summary>
	<brief_title>A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Women with advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy (surgery and/or radiotherapy). Patient has a histologically and/or cytologically confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive breast cancer Patient has HER2negative breast cancer Patient has adequate bone marrow and organ function Patient who received any CDK4/6 inhibitor. Patient has a known hypersensitivity to any of the excipients of LEE011 or letrozole Patients with inflammatory breast cancer. Patient who received any prior systemic anticancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer Patient is currently using other anticancer therapy Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major side effects. Patient who has received radiotherapy â‰¤ 4 weeks Patient has a concurrent malignancy or malignancy within 3 years Patient has metastases to the central nervous system (CNS). Patient has a known history of HIV infection Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Advanced breast cancer</keyword>
	<keyword>Hormone receptor positive</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>LEE011,</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Postmenopausal Asian women</keyword>
	<keyword>Pre and Postmenopausal Japanese women</keyword>
</DOC>